TickerFacts.

Burning Rock Biotech Ltd (BNR): Cash & Equivalents

Annual figures by period end, from SEC filings.

478.39M CNY
As of 2025-12-31
-19.2%
3-year compound annual growth
-24.1%
5-year compound annual growth
1.90B CNY2018-12-31: 93.34M CNY2019-12-31: 94.23M CNY2020-12-31: 1.90B CNY2021-12-31: 1.43B CNY2022-12-31: 905.45M CNY2023-12-31: 615.10M CNY2024-12-31: 519.85M CNY2025-12-31: 478.39M CNY478.39M CNY
2018-12-31 Cash & Equivalents (CNY) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31478.39M CNY-8.0%2026-04-28, Balance as of period end
2024-12-31519.85M CNY-15.5%2026-04-28, Balance as of period end
2023-12-31615.10M CNY-32.1%2026-04-28, Balance as of period end
2022-12-31905.45M CNY-36.7%2025-04-29, Balance as of period end
2021-12-311.43B CNY-24.5%2024-04-29, Balance as of period end
2020-12-311.90B CNYn/m2023-04-20, Balance as of period end
2019-12-3194.23M CNY+1.0%2022-04-29, Balance as of period end
2018-12-3193.34M CNYn/a2021-03-23, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Burning Rock Biotech Ltd (BNR)2025-12-31478.39M CNY-8.0%
Concord Medical Services Holdings Ltd (CCM)2025-12-31297.79M CNY+37.7%

Compare BNR, CCM side by side · Screen every company in Services-Medical Laboratories ↗